大剂量化疗联合自体干细胞移植治疗鼻咽部T细胞淋巴瘤  

High-dose chemotherapy/autologous stem cell transplantation for nasopharyngeal T cell lymphoma

作　　者：刘贤明[1] 张会来[1] 崔秀珍[1] 王华庆[1] 

机构地区：[1]天津医科大学附属肿瘤医院淋巴瘤科,天津市“肿瘤防治”重点实验室,中美淋巴血液肿瘤诊治中心,300060

出　　处：《中华血液学杂志》2010年第8期515-518,共4页Chinese Journal of Hematology

摘　　要：目的 评价大剂量化疗联合自体干细胞移植治疗鼻咽部T细胞淋巴瘤的价值.方法 回顾性分析天津医科大学附属肿瘤医院1995年1月至2007年1月接受大剂量放化疗联合自体干细胞移植治疗的51例鼻咽部T细胞淋巴瘤患者.结果 在51例行自体干细胞移植的患者中,无移植相关性死亡;16例患者在移植后出现复发,其中2例经过抢救性化疗在复发后91和56个月仍然存活,余14例患者死于肿瘤进展.1年、3年及5年的总生存（OS）率分别为98.0%、84.0%及72.0%.1年、3年及5年的无进展生存（PFS）率分别为90.2%、78.4%及66.7%.单因素分析显示临床分期、B症状和IPI评分是影响鼻咽部T细胞淋巴瘤预后的相关因素（P值分别为0.041、0.036和0.031）.结论 大剂量化疗联合自体干细胞移植治疗鼻咽部T细胞淋巴瘤可显著提高患者的治愈率并延长其生存时间.Objective To evaluate the role of high-dose chemotherapy （HCT）/autologous stem cell transplantation（ASCT） for nasopharyngeal T cell lymphomas. Methods A retrospective review of 51 patients who underwent HCT/ASCT between January 1995 and January 2007. Results Of the 51 patients who underwent ASCT, no treatment-related death was seen; sixteen patients relapsed after transplant, two patients are still alive through salvage chemotherapy 91 months and 56 months after relapse, the other fourteen patients died in tumor progression. 1-year, 3-year and 5-year overall survival （OS） rates were 98.0%, 84.0% and 72.0% , respectively, 1-year, 3-year and 5-year progression-free survival （PFS） rates were 90.2%, 78.4% and 66.7%, respectively. Univariate analysis showed that clinical stage, B symptom and IPI were prognostic factors for patients with nasopharyngeal T cell lymphomas, the P value being 0. 041,0.036 and 0.031, respectively. Conclusion High-dose therapy/autologous stem cell transplantation can improve cure rate and prolong survival time significantly in patients with nasopharyngeal T cell lymphomas.

关 键 词：自体干细胞移植 鼻咽部 淋巴瘤 

分 类 号：R739.63[医药卫生—肿瘤]